June 2026 in “Saudi Medical Horizons Journal” JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
April 2026 in “Nowotwory Journal of Oncology” Aesthetic treatments can safely improve cancer patients' quality of life with oncologist approval.
April 2026 in “International Journal of Drug Delivery Technology” Alopecia can often be managed effectively with various treatments, but early diagnosis is crucial for preventing permanent hair loss.
STS01 1% effectively promotes hair regrowth with minimal side effects.
April 2026 in “Journal of Pharmaceutical Investigation” Nanotechnology could improve treatment for scars and atopic dermatitis by targeting skin issues more effectively.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
March 2026 in “Nature Communications” Genetic factors, skin barrier, immune function, and obesity influence risk of fungal skin infections.
February 2026 in “Frontiers in Immunology” Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.
Elderly skin care needs personalized treatment, early intervention, and integrated psychiatric care.
February 2026 in “Eduvest - Journal Of Universal Studies” Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata cases in children are rising, especially in females and low-income regions, with a projected increase in China and decrease in the USA.
January 2026 in “Forum Dermatologicum” Hair loss can be caused by cancer, treatments, or skin conditions, and trichoscopy helps diagnose it.
January 2026 in “Dermatology Practical & Conceptual” Children with alopecia areata often have vitiligo, allergic asthma, ADHD, and low vitamin B12 and ferritin levels.
January 2026 in “Frontiers in Immunology” Timely treatment of eosinophilic asthma in rheumatic disease patients can prevent organ damage.
January 2026 in “Frontiers in Medicine” Alopecia areata in Taiwan has a high disease burden and needs better research and diagnostic criteria.
January 2026 in “Clinical Cosmetic and Investigational Dermatology” Early diagnosis and targeted anti-inflammatory treatments can improve outcomes in androgenetic alopecia with perifollicular inflammation and fibrosis.
January 2026 in “Journal of Cosmetics Dermatological Sciences and Applications” PRP shows promise for hair restoration with mild side effects, but more research is needed for clear guidelines.
December 2025 in “Journal of AI” The USA, China, Italy, and Türkiye lead in diverse PRP research, focusing on healing and pain management.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
December 2025 in “MEDFARM Jurnal Farmasi dan Kesehatan” Topical metformin shows promise for treating skin conditions like acne and psoriasis.
December 2025 in “Lviv clinical bulletin” PRP therapy may help with ovarian issues and fertility, but more research is needed.
December 2025 in “International Journal of Pharmacology” iPSC-derived artificial platelets show promise for consistent and effective regenerative therapies.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
December 2025 in “ADMET & DMPK” Personalized treatments for hair loss focus on specific genetic and biological pathways.
Autologous platelet concentrates help heal and regenerate dental tissues.
November 2025 in “Frontiers in Immunology” Stem cell activity influences autoimmune disease outcomes by affecting immune responses and tissue regeneration.
November 2025 in “Journal of Disease and Public Health” Post-COVID-19 syndrome is complex, affects 5%-10% of people, and requires better research and global collaboration for treatment.
November 2025 in “Frontiers in Medicine” Baseline severity and relapse history affect alopecia areata treatment and recurrence.
November 2025 in “Frontiers in Medicine” The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.